Ovid Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
OVID$2.80-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| (in thousands) | For the Year Ended December 31, 2024 | For the Year Ended December 31, 2023 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(26,433) | $(52,339) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Change in fair value of royalty monetization liability | (30,000) | — |
| Unrealized (gain) loss on equity investments | (3,349) | (2,003) |
| Change in accrued interest and accretion of discount on marketable securities | (2,765) | (2,172) |
| Stock-based compensation expense | 6,276 | 7,285 |
| Depreciation and amortization expense | 613 | 568 |
| Noncash operating lease expense | 1,097 | 1,028 |
| Change in lease liability | (1,246) | (534) |
| Change in operating assets and liabilities: | — | — |
| Prepaid expenses and other current assets | 899 | (1,385) |
| Accounts payable | (512) | 1,750 |
| Accrued expenses | (537) | 2,021 |
| Net cash used in operating activities | (55,956) | (45,781) |
| Cash flows from investing activities: | ||
| Purchase of marketable securities | (73,246) | (112,443) |
| Sales/maturities of marketable securities | 128,000 | 120,000 |
| Purchase of long-term equity investment | — | (10,000) |
| Purchases of property and equipment | (71) | (40) |
| Software development and other costs | (90) | (97) |
| Net cash provided by (used in) investing activities | 54,594 | (2,581) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of options and employee stock purchase plan | 622 | 535 |
| Proceeds from royalty monetization agreement | — | 30,000 |
| Net cash provided by financing activities | 622 | 30,535 |
| Net decrease in cash, cash equivalents and restricted cash | (740) | (17,826) |
| Cash, cash equivalents and restricted cash, at beginning of period | 28,972 | 46,799 |
| Cash, cash equivalents and restricted cash, at end of period | $28,232 | $28,972 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.